Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden

Table 5 Summary findings of budget impact analysis

	Year					Cumulative budget impact over 5 yr
	1	2	3	4	5
Sweden
Total treatment-eligible patients, n1	158	158	158	158	158	―
Projected market share for 177Lu-Dotatate, %2	30	60	80	90	90	―
Total cost if 177Lu-Dotatate adopted, SEK	85610153	102881530	114640765	120520382	120520382	544173212
Total cost if 177Lu-Dotatate not adopted, SEK	68338777	68338777	68338777	68338777	68338777	341693885
Budget impact, SEK	17271376	34542753	46301988	52181605	52181605	202479327
Norway
Total treatment-eligible patients, n1	100	100	100	100	100	―
Projected market share for 177Lu-Dotatate, %2	50	50	50	50	50	―
Total cost if 177Lu-Dotatate adopted, NOK	67920975	67920975	67920975	67920975	67920975	339604875
Total cost if 177Lu-Dotatate not adopted, NOK	44438750	44438750	44438750	44438750	44438750	222193750
Budget impact, NOK	23482225	23482225	23482225	23482225	23482225	117411125

¹Number of patients annually with metastatic GEP-NEPs based on an estimated incidence of 5.25 per 100000 population (Oberg et al[4], 2012) (40% of patients with GEP-NETs assumed to have metastases) and population estimates from national statistics agencies.

²Assumes that all other eligible patients are treated with everolimus.